| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 1, 2016
LEXINGTON, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Dec 5, 2015Curis expects to initiate a randomized Phase 2 trial in patients with relapsed/refractory DLBCL with MYC alterations
LEXINGTON, Mass., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Dec 2, 2015
LEXINGTON, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 8, 2015
LEXINGTON, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 8, 2015Management to Host Conference Call Today at 8:30 a.m. EST
LEXINGTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 5, 2015
LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 2, 2015
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 2, 2015
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 19, 2015Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology
LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 14, 2015
LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...